Annonay

Researchers are evaluating the effectiveness, safety, and behavior of a new treatment called sefaxersen (RO7434656), an Antisense Oligonucleotide (ASO) therapy, for people with primary IgA nephropathy (IgAN). The study focuses on participants who have a high risk of their kidney disease worsening despite receiving the best available supportive care. This is a Phase III, randomized, double-blind, placebo-controlled trial conducted at multiple centers. Participants will receive either sefaxersen or a matching placebo through subcutaneous injections according to a specified schedule. The study compares these two groups to see how the treatment affects kidney function over time. The intervention is designed to inhibit Complement Factor B, which is involved in the disease process. The study includes vaccination requirements and contraceptive use for women of childbearing potential to ensure safety. During the study, participants will be monitored for changes in their urine protein-to-creatinine ratio (UPCR) at baseline and at week 37, which is the primary measure of kidney function improvement. Other assessments include kidney biopsy results, kidney function tests estimating glomerular filtration rate (eGFR), and ongoing safety evaluations. The trial tracks participants' health closely to assess the treatment's effect and any side effects throughout the study period.

Researchers are studying the impact of a brief motivational intervention (BMI) conducted by pharmacists to help reduce the use of benzodiazepines and related drugs (BZD/Z) in adults who have been using these medications long-term. The study addresses the growing use and prolonged prescriptions of these drugs in France, where long-term use often exceeds recommended limits and can lead to adverse effects. The goal is to see if this short-term, pharmacy-based approach can support patients in safely reducing their medication dose without worsening anxiety or sleep disorder symptoms. Participants will be divided into groups receiving either the brief motivational intervention or usual pharmacy dispensing practices. The intervention involves pharmacists identifying patients on long-term BZD/Z treatment and applying motivational techniques to encourage dose reduction. The study focuses on adults with continuous BZD/Z use for at least six months. The researchers will evaluate changes in daily drug dose and monitor any clinical worsening over a six-month period. Throughout the study, participants will be assessed for medication use and symptom changes related to anxiety and sleep disorders. Researchers will collect data on the daily dose of BZD/Z and track any clinical worsening at six months. The study includes informed consent, patient understanding assessments, and affiliation with the French social security system. The outcomes will help determine the feasibility and impact of pharmacist-led interventions for deprescribing BZD/Z in adults.

Nearly half of patients who stay in intensive care experience anxiety and depression afterward, with about one in five developing post-traumatic stress disorder. Improving the ICU patient experience is important, and efforts focus on creating a familiar environment. Animal-assisted therapies have been used successfully in various patient groups, especially elderly or those with cognitive or psychiatric conditions, showing benefits for anxiety and mood. However, allowing patients to be visited by their own pets in the ICU is rare due to concerns about animal behavior and infection risks, despite authorization in many facilities. This study evaluates the feasibility of allowing conscious adult ICU patients to be visited by their own pets, such as dogs or cats, for 20 minutes. Participants are patients who have recovered from the acute phase or are in rehabilitation or end-of-life care, with no hemodynamic or respiratory failure. The study focuses on whether pet visits are possible and safe in this context. Participants will be monitored for their ability to have pet visits, with the main outcome measured on day 15 regarding the feasibility of these visits. The study excludes patients with unstable acute conditions, mechanical ventilation, tracheostomy, immunosuppression, multi-resistant bacteria carriage, behavioral or consciousness disorders, pregnancy, significant skin wounds or burns, guardianship, or language barriers. Participation requires informed consent and social security coverage.